Natus announces sale of Medix business
As part of this divestiture, Natus will sell the Medix line of products, including incubators, warmers and other Medix products. Under its new ownership, Medix will continue to
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XAs part of this divestiture, Natus will sell the Medix line of products, including incubators, warmers and other Medix products. Under its new ownership, Medix will continue to
Shandong has previously paid Guided Therapeutics nearly $1 million in license payments and invested upwards to another $1 million in infrastructure in China for the roll out of
The collaboration between Lantheus and Cerevast Medical is claimed to help Lantheus in identifying new applications for its microbubble franchise and to expand into new disease areas such
As per Channel Medsystems, the Cerene device offers cryotherapy to freeze the lining of the uterus to significantly reduce future menstrual bleeding. The design of the device and
The rebranding strategy reflects the company’s strategic focus on advancing treatment solutions in urology and stone management for global patients. The rebranding follows Advanced MedTech’s recent spin out
The full study, entitled “Comparative Human Factors Evaluation of Two Nasal Naloxone Administration Devices: NARCAN Nasal Spray and Naloxone Prefilled Syringe with Nasal Atomizer,” was published in Pain
“We are delivering a solution that provides clinical information and analytics even faster in a more secure manner,” says Shashi Tripathi, chief technology officer, ImpediMed. “This will make
As per FEops, HEARTguide is a cloud-based procedure planning environment, offering advanced personalized computational modeling and simulation to provide clinicians and medical device manufacturers with preoperative insights into
AngioDynamics said that its DIRECT study supports the expanded indication for the NanoKnife system in treating stage III pancreatic cancer. Last January, the FDA granted Breakthrough Device Designation
With the medical device license, Nexstim can now begin marketing and selling of its NBS system and NexSpeech in Canada. The company had already signed a distribution agreement